Characterizing Microstructural Differences of Semisolid Topical Dosage Forms

The company is expanding its US manufacturing and R&D capabilities with a $1 billion investment by 2030.

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

The company’s mocravimod, a novel oral S1P receptor, is being evaluated for its efficacy as an addition to CAR-T cell therapies.

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

The 12th edition of the European Pharmacopoeia will be an all-digital, redesigned, user-friendly issue.

mRNA technologies offer great promise in immunotherapy and non-immunogenic applications.